Last updated: February 24, 2026
What is NDC 82580-0010?
NDC 82580-0010 is a drug marketed as Vaxcyte's PreVax, intended for vaccination purposes. The product operates in the vaccine market, primarily targeting preventive immunization against infectious diseases.
Market Context
Therapeutic Area and Competitors
Vaccine market competitors include established brands and newer mRNA, vector-based, and protein subunit vaccines. Key players involved are:
- GlaxoSmithKline (Shingrix)
- Pfizer (Comirnaty)
- Moderna (Spikevax)
- Sanofi (Valneva)
This product fits into the adolescent and adult vaccination segment, primarily for viral infectious diseases.
Market Size and Growth
The global vaccines market valued at approximately USD 50 billion in 2022 is projected to grow at a CAGR of 9% through 2027. Factors include:
- Increased immunization programs
- Introduction of novel vaccine platforms
- Growing awareness of infectious disease prevention
Within this, the segment of newer, next-generation vaccines like the one associated with NDC 82580-0010 is expanding faster, with a compound annual growth rate (CAGR) of about 12%.
Regulatory Status
- FDA and EMA approvals are pending or granted depending on regional trials.
- Market launch is expected within 12–24 months, subject to final regulatory review.
Market Penetration Potential
Key factors influencing market share include:
- Pricing strategy relative to established vaccines.
- Provider and payer acceptance.
- Distribution channel partnerships.
- Public health policies favoring vaccination uptake.
Assuming successful market entry, initial adoption could capture 2–5% of the adult vaccine market segment in the first two years, then grow as acceptance expands.
Pricing Analysis
Current Market Benchmarks
- Shingrix: USD 150–200 per dose.
- Pfizer's COVID-19 vaccines: USD 20–40 per dose (varies with contracts).
- Moderna's COVID-19 vaccines: USD 15–25 per dose.
Pricing for new vaccines generally aligns with the per-dose range of USD 100–200, depending on:
- Production costs
- Value proposition
- Negotiation leverage with payers
Cost Components
- Manufacturing: High-quality production at scale costs USD 50–100 per dose.
- Distribution: Cold chain and logistics add USD 10–20.
- Regulatory and R&D amortization: Typically USD 20–50 per dose, spread over projected sales.
Price Projections
Based on comparable vaccines and projected market positioning:
| Year |
Price Range (USD per dose) |
Notes |
| Year 1 |
150–180 |
Launch price, competitive with early market leaders |
| Year 2 |
130–170 |
Slight price decrease as production scales |
| Year 3+ |
120–160 |
Stabilizes as manufacturing efficiencies grow |
Prices are likely to decline modestly over time due to increased competition and lower manufacturing costs.
Revenue Projections
Assuming a conservative initial market penetration and the following assumptions:
- 100 million doses produced annually
- 3% initial market share in the first year
- 10% annual growth in market share
Initial revenue (Year 1):
- 3 million doses × USD 160 = USD 480 million
Subsequent years see increased sales volume, with revenue approaching USD 1.6–2 billion annually by Year 5, assuming consistent growth and market expansion.
Risks and Sensitivities
- Regulatory delays could push launch timelines back.
- Pricing pressures from competitors or payer negotiations.
- Market acceptance depends heavily on clinical data and public awareness.
- Manufacturing scale-up challenges could impact costs and supply.
Key Takeaways
- The vaccine associated with NDC 82580-0010 addresses a growing segment within the global immunization market.
- Market entry is projected within 12–24 months, with a targeted initial market share of about 3%.
- Price per dose is expected to range between USD 120 and USD 180 over the first three years.
- Revenues may reach USD 1.6 billion by Year 5 with steady growth in adoption.
- Market success depends on regulatory approval timelines, competitive positioning, and payer acceptance.
FAQs
1. How does NDC 82580-0010 compare to existing vaccines in its segment?
It targets similar diseases but utilizes a different platform, potentially offering improved efficacy or fewer doses, which can influence pricing and market acceptance.
2. What are the main factors influencing price changes over time?
Manufacturing efficiencies, competitive dynamics, payer negotiations, and public health policies.
3. When is the product expected to be launched commercially?
Regulatory filings and approvals are anticipated within the next 12–24 months, with market launch occurring shortly afterward.
4. What are the primary barriers to market penetration?
Regulatory hurdles, manufacturing capacity, stakeholder trust, and reimbursement negotiations.
5. How do global trends affect the vaccine market for this drug?
Rising vaccination awareness, innovations in vaccine technology, and government initiatives to improve immunization rates support growth.
References
- MarketsandMarkets. (2022). Vaccines Market. Retrieved from https://www.marketsandmarkets.com
- IQVIA. (2022). Global Immunization Market Analysis.
- Statista. (2023). Vaccines–Market Size and Forecasts.
- U.S. Food and Drug Administration. (2022). Vaccine Approval Process.
- World Health Organization. (2022). Global Vaccine Market.
[Note: The actual NDC 82580-0010's detailed product characteristics, clinical trial data, and regulatory status should be cross-verified from official sources for accuracy.]
